Key points are not available for this paper at this time.
Abstract N 6 -methyladenosine (m 6 A) is the most prevalent and well-characterized internal chemical modification in eukaryotic RNA, influencing gene expression and phenotypic changes by controlling RNA fate. Insulin-like growth factor-2 mRNA-binding proteins (IGF2BPs) preferentially function as m 6 A effector proteins, promoting stability and translation of m 6 A-modified RNAs. IGF2BPs, particularly IGF2BP1 and IGF2BP3, are widely recognized as oncofetal proteins predominantly expressed in cancer rather than normal tissues, playing a critical role in tumor initiation and progression. Consequently, IGF2BPs hold potential for clinical applications and serve as a good choice for targeted treatment strategies. In this review, we discuss the functions and mechanisms of IGF2BPs as m 6 A readers and explore the therapeutic potential of targeting IGF2BPs in human cancer.
Zhu et al. (Tue,) studied this question.